Developer docs
API playgroundTry for free, no card

Search company profiles

Gencurix

Full company profile

uuid0000myc

Namestring
Gencurix
Legal namestring
Gencurix
Websiteurl
gencurix.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Gencurix is a South Korea-based molecular diagnostics company, founded in 2011 and headquartered in Seoul, that develops digital PCR-based companion diagnostic tests for precision oncology. Its product portfolio centers on the Droplex PIK3CA Test for breast cancer and four cancer gene mutation tests targeting POLE (endometrial cancer), KRAS (colorectal cancer), BRAF (thyroid cancer), and cMET (non-small cell lung cancer). The company employs 51-100 people and has secured approximately $55.8M in cumulative funding across rounds in 2018 and 2021.

The company's underlying technology is a digital PCR platform combined with proprietary biomarker discovery capabilities, designed to deliver high-sensitivity mutation detection for targeted therapy selection and minimal residual disease monitoring. Gencurix monetizes through one-time license sales of its IVD products, monetizing regulatory clearances in target markets rather than building direct commercial infrastructure. Its go-to-market relies on channel partnerships: Bio-Rad Laboratories holds exclusive supply and sales rights across 32 European countries, QIAGEN provides global commercial infrastructure through the QIAcuityDx Partnering Program, Roche Diagnostics is engaged in co-commercialization discussions, and Hitachi High-Tech leads Japan market entry.

Gencurix serves oncology laboratories, healthcare providers, and government health systems requiring CE-IVDR or local regulator-grade companion diagnostics. Its primary customer segments are vertical use cases in breast, endometrial, colorectal, thyroid, and non-small cell lung cancer diagnostics. The company has CE-IVDR certification for its four multi-cancer tests and Thailand FDA approval for the Droplex PIK3CA Test, with stated expansion intent across Southeast Asia (Vietnam, Malaysia), Eastern Europe (Slovenia), and Japan.

Short descriptiontext

Gencurix is a Seoul-based molecular diagnostics company developing digital PCR-based companion diagnostic tests for cancer, distributed globally through partnerships with Bio-Rad, QIAGEN, Roche Diagnostics, and Hitachi High-Tech.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
cancer companion diagnostics, digital PCR tests, molecular diagnostics, in vitro diagnostics, precision oncology assays
Industry3 codes
PRIMARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Companion Diagnostics (Molecular Diagnostics / IVD)
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Digital PCR-based Companion Diagnostics
TypeOne Time License
Description

Revenue from digital PCR-based in vitro diagnostic products including the Droplex PIK3CA Test for breast cancer companion diagnostics. Products are sold through regulatory approvals in target markets and distributed via channel partners.

koreabiomed.com
2CE-IVDR Certified Cancer Gene Tests
TypeOne Time License
Description

Revenue from CE-IVDR certified cancer gene mutation tests (POLE, KRAS, BRAF, cMET) sold across Europe through Bio-Rad exclusive supply and sales contract covering 32 European countries.

mk.co.kr
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Droplex PIK3CA Test
Description

Digital PCR-based breast cancer companion diagnostic test

koreabiomed.com
Core offering1 text field

Gencurix develops and sells digital PCR-based companion diagnostic (CDx) tests for precision oncology, detecting cancer-driving gene mutations to guide targeted therapy selection. Its product portfolio includes the Droplex PIK3CA Test for breast cancer and four CE-IVDR certified cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer). Products are sold as in vitro diagnostic kits/reagents to healthcare providers and laboratories globally through channel partners and direct market entries.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Gencurix is a cancer molecular diagnostics company offering a portfolio of digital PCR-based companion diagnostic tests for precision oncology. The company's product portfolio includes the Droplex PIK3CA Test for breast cancer and a suite of cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer). These tests are designed to detect specific genetic mutations to guide targeted therapy selection and monitoring in cancer treatment. The products operate on digital PCR technology platforms and have received regulatory approvals including CE-IVDR certification for European markets and Thailand FDA approval for select products.

Product and service5 records
1Droplex PIK3CA Test
CategoryCancer Companion Diagnostics (Molecular Diagnostics)
Description

Digital PCR-based breast cancer companion diagnostic test that detects PIK3CA mutations in patient samples to guide targeted therapy selection for breast cancer patients. Approved by Thailand FDA and used by hospital laboratories and oncology centers.

2POLE Test
CategoryCancer Companion Diagnostics (Molecular Diagnostics)
Description

Digital PCR-based cancer gene mutation test for detecting POLE mutations in endometrial cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.

3KRAS Test
CategoryCancer Companion Diagnostics (Molecular Diagnostics)
Description

Digital PCR-based cancer gene mutation test for detecting KRAS mutations in colorectal cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.

4BRAF Test
CategoryCancer Companion Diagnostics (Molecular Diagnostics)
Description

Digital PCR-based cancer gene mutation test for detecting BRAF mutations in thyroid cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.

5cMET Test
CategoryCancer Companion Diagnostics (Molecular Diagnostics)
Description

Digital PCR-based cancer gene mutation test for detecting cMET mutations in non-small cell lung cancer (NSCLC). CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-22
Description

Exclusive supply and sales contract with Bio-Rad Laboratories covering 32 European countries. Gencurix products converted from IVDD to stricter IVDR system with Bio-Rad distribution. Partnership covers all existing product lines including cancer gene mutation tests (POLE, KRAS, BRAF, cMET).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-18
Description

QIAcuity Digital PCR IVD assay development partnership for oncology assays on QIAcuityDx platform. Gencurix is inaugural partner in QIAGEN's new QIAcuityDx Partnering Program. Collaboration aims to create multiplex IVD assays for tissue and liquid biopsy applications. Gencurix responsible for regulatory approvals, leveraging QIAGEN's global commercial infrastructure.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Engaged in co-commercialization discussions with Roche Diagnostics. Foundations for joint development and global commercialization cooperation in molecular diagnostics taking shape. Partnership discussions part of global expansion strategy.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-08-28
Description

Partnership to develop cancer molecular diagnostics business and launch testing services in Japan. Combines Hitachi High-Tech's R&D and manufacturing expertise with Gencurix's biomarker discovery technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Asuragen, a Bio-Techne company, is a direct peer developing companion diagnostics and molecular oncology assays including BRAF, KRAS, and other cancer mutation tests. Highly comparable in CDx focus and oncology gene mutation testing portfolio.

TypeBroad incumbent
Description

QIAGEN is both a Gencurix partner and a broad incumbent in molecular diagnostics with the QIAcuity digital PCR platform. Comparable through its QIAcuityDx clinical dPCR system and oncology IVD assay development program that overlaps directly with Gencurix's product strategy.

TypeBroad incumbent
Description

Bio-Rad is Gencurix's exclusive European distributor and a major digital PCR incumbent via its QXDx ddPCR system. Comparable as both a competing dPCR platform provider and a channel partner in oncology molecular diagnostics.

TypeDirect peer
Description

Amoy Diagnostics is an Asia-based precision oncology company specializing in companion diagnostics for EGFR, KRAS, BRAF, and other cancer gene mutations. Directly comparable in CDx product portfolio, Asian market positioning, and oncology gene mutation test focus.

TypeDirect peer
Description

Burning Rock Biotech is a China-based precision oncology diagnostics company offering NGS-based cancer gene mutation testing and companion diagnostics. Comparable as an Asian-headquartered oncology CDx company with international distribution ambitions.

TypeBroad incumbent
Description

Roche Diagnostics is in co-commercialization discussions with Gencurix and operates broadly in molecular diagnostics including PCR-based oncology tests and companion diagnostics. Comparable as a global incumbent whose diagnostics division overlaps significantly with Gencurix's target markets.

TypeBroad incumbent
Description

Exact Sciences is a precision oncology diagnostics company with Cologuard and the Oncotype DX franchise. Comparable as a precision diagnostics company commercializing cancer-related molecular tests at scale.

TypeEmerging player
Description

Guardant Health is a precision oncology company specializing in liquid biopsy and blood-based cancer mutation profiling for therapy selection. Comparable in oncology CDx and gene mutation detection, though focused on liquid biopsy rather than tissue-based dPCR.

TypeEmerging player
Description

Personalis is a precision oncology company offering tumor profiling and companion diagnostics services via NextGen sequencing. Comparable as a precision oncology player developing CDx products, though platform technology differs from Gencurix's dPCR focus.

TypeBroad incumbent
Description

NeoGenomics is a US-based oncology diagnostics company providing comprehensive cancer testing services including molecular and genetic profiling. Comparable as a commercial-stage oncology diagnostics company with multi-cancer testing menu.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gencurix

Cancer Companion Diagnostics (Molecular Diagnostics / IVD)gencurix.com

Gencurix is a Seoul-based molecular diagnostics company developing digital PCR-based companion diagnostic tests for cancer, distributed globally through partnerships with Bio-Rad, QIAGEN, Roche Diagnostics, and Hitachi High-Tech.

What Gencurix does

Gencurix is a South Korea-based molecular diagnostics company, founded in 2011 and headquartered in Seoul, that develops digital PCR-based companion diagnostic tests for precision oncology. Its product portfolio centers on the Droplex PIK3CA Test for breast cancer and four cancer gene mutation tests targeting POLE (endometrial cancer), KRAS (colorectal cancer), BRAF (thyroid cancer), and cMET (non-small cell lung cancer). The company employs 51-100 people and has secured approximately $55.8M in cumulative funding across rounds in 2018 and 2021.

The company's underlying technology is a digital PCR platform combined with proprietary biomarker discovery capabilities, designed to deliver high-sensitivity mutation detection for targeted therapy selection and minimal residual disease monitoring. Gencurix monetizes through one-time license sales of its IVD products, monetizing regulatory clearances in target markets rather than building direct commercial infrastructure. Its go-to-market relies on channel partnerships: Bio-Rad Laboratories holds exclusive supply and sales rights across 32 European countries, QIAGEN provides global commercial infrastructure through the QIAcuityDx Partnering Program, Roche Diagnostics is engaged in co-commercialization discussions, and Hitachi High-Tech leads Japan market entry.

Gencurix serves oncology laboratories, healthcare providers, and government health systems requiring CE-IVDR or local regulator-grade companion diagnostics. Its primary customer segments are vertical use cases in breast, endometrial, colorectal, thyroid, and non-small cell lung cancer diagnostics. The company has CE-IVDR certification for its four multi-cancer tests and Thailand FDA approval for the Droplex PIK3CA Test, with stated expansion intent across Southeast Asia (Vietnam, Malaysia), Eastern Europe (Slovenia), and Japan.

Gencurix firmographics

Firmographics
Name
Gencurix
Legal name
Gencurix
Website
https://gencurix.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Gencurix is a Seoul-based molecular diagnostics company developing digital PCR-based companion diagnostic tests for cancer, distributed globally through partnerships with Bio-Rad, QIAGEN, Roche Diagnostics, and Hitachi High-Tech.
Ownership category
akta.pro rank

Gencurix industry classification

Industry
Product category
Cancer Companion Diagnostics (Molecular Diagnostics / IVD)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Cancer companion diagnostics
  • Digital PCR tests
  • Molecular diagnostics
  • In vitro diagnostics
  • Precision oncology assays

Where Gencurix is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Markets served

Gencurix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Digital PCR-based Companion Diagnostics: Revenue from digital PCR-based in vitro diagnostic products including the Droplex PIK3CA Test for breast cancer companion diagnostics. Products are sold through regulatory approvals in target markets and distributed via channel partners.
  2. CE-IVDR Certified Cancer Gene Tests: Revenue from CE-IVDR certified cancer gene mutation tests (POLE, KRAS, BRAF, cMET) sold across Europe through Bio-Rad exclusive supply and sales contract covering 32 European countries.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels2 records

Gencurix product offering

Product offering

Core offering

Gencurix develops and sells digital PCR-based companion diagnostic (CDx) tests for precision oncology, detecting cancer-driving gene mutations to guide targeted therapy selection. Its product portfolio includes the Droplex PIK3CA Test for breast cancer and four CE-IVDR certified cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer). Products are sold as in vitro diagnostic kits/reagents to healthcare providers and laboratories globally through channel partners and direct market entries.

Product overview

Gencurix is a cancer molecular diagnostics company offering a portfolio of digital PCR-based companion diagnostic tests for precision oncology. The company's product portfolio includes the Droplex PIK3CA Test for breast cancer and a suite of cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer). These tests are designed to detect specific genetic mutations to guide targeted therapy selection and monitoring in cancer treatment. The products operate on digital PCR technology platforms and have received regulatory approvals including CE-IVDR certification for European markets and Thailand FDA approval for select products.

Differentiator

Problem solved

Functional benefit

Brands

  • Droplex PIK3CA Test: Digital PCR-based breast cancer companion diagnostic test

Products and services

  • Droplex PIK3CA Test Digital PCR-based breast cancer companion diagnostic test that detects PIK3CA mutations in patient samples to guide targeted therapy selection for breast cancer patients. Approved by Thailand FDA and used by hospital laboratories and oncology centers.
  • POLE Test Digital PCR-based cancer gene mutation test for detecting POLE mutations in endometrial cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.
  • KRAS Test Digital PCR-based cancer gene mutation test for detecting KRAS mutations in colorectal cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.
  • BRAF Test Digital PCR-based cancer gene mutation test for detecting BRAF mutations in thyroid cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.
  • cMET Test Digital PCR-based cancer gene mutation test for detecting cMET mutations in non-small cell lung cancer (NSCLC). CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.

Companies that use Gencurix

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Gencurix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Gencurix partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and strategic.

  • Bio-Rad LaboratoriescoreChannel Partner/ Reseller/ Distributor · 22 January 2026Exclusive supply and sales contract with Bio-Rad Laboratories covering 32 European countries. Gencurix products converted from IVDD to stricter IVDR system with Bio-Rad distribution. Partnership covers all existing product lines including cancer gene mutation tests (POLE, KRAS, BRAF, cMET).
  • QIAGENcoreStrategic or Co-development Partner · 18 June 2025QIAcuity Digital PCR IVD assay development partnership for oncology assays on QIAcuityDx platform. Gencurix is inaugural partner in QIAGEN's new QIAcuityDx Partnering Program. Collaboration aims to create multiplex IVD assays for tissue and liquid biopsy applications. Gencurix responsible for regulatory approvals, leveraging QIAGEN's global commercial infrastructure.
  • Roche DiagnosticsstrategicStrategic or Co-development Partner · 1 January 2025Engaged in co-commercialization discussions with Roche Diagnostics. Foundations for joint development and global commercialization cooperation in molecular diagnostics taking shape. Partnership discussions part of global expansion strategy.
  • Hitachi High-TechstrategicStrategic or Co-development Partner · 28 August 2024Partnership to develop cancer molecular diagnostics business and launch testing services in Japan. Combines Hitachi High-Tech's R&D and manufacturing expertise with Gencurix's biomarker discovery technology.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Gencurix competitors and assessment

Company assessment

Direct peers

  • Asuragen (Bio-Techne): Asuragen, a Bio-Techne company, is a direct peer developing companion diagnostics and molecular oncology assays including BRAF, KRAS, and other cancer mutation tests. Highly comparable in CDx focus and oncology gene mutation testing portfolio.
  • Amoy Diagnostics: Amoy Diagnostics is an Asia-based precision oncology company specializing in companion diagnostics for EGFR, KRAS, BRAF, and other cancer gene mutations. Directly comparable in CDx product portfolio, Asian market positioning, and oncology gene mutation test focus.
  • Burning Rock Biotech: Burning Rock Biotech is a China-based precision oncology diagnostics company offering NGS-based cancer gene mutation testing and companion diagnostics. Comparable as an Asian-headquartered oncology CDx company with international distribution ambitions.

Broad incumbents

  • QIAGEN: QIAGEN is both a Gencurix partner and a broad incumbent in molecular diagnostics with the QIAcuity digital PCR platform. Comparable through its QIAcuityDx clinical dPCR system and oncology IVD assay development program that overlaps directly with Gencurix's product strategy.
  • Bio-Rad Laboratories: Bio-Rad is Gencurix's exclusive European distributor and a major digital PCR incumbent via its QXDx ddPCR system. Comparable as both a competing dPCR platform provider and a channel partner in oncology molecular diagnostics.
  • Roche Diagnostics: Roche Diagnostics is in co-commercialization discussions with Gencurix and operates broadly in molecular diagnostics including PCR-based oncology tests and companion diagnostics. Comparable as a global incumbent whose diagnostics division overlaps significantly with Gencurix's target markets.
  • Exact Sciences: Exact Sciences is a precision oncology diagnostics company with Cologuard and the Oncotype DX franchise. Comparable as a precision diagnostics company commercializing cancer-related molecular tests at scale.
  • NeoGenomics: NeoGenomics is a US-based oncology diagnostics company providing comprehensive cancer testing services including molecular and genetic profiling. Comparable as a commercial-stage oncology diagnostics company with multi-cancer testing menu.

Emerging players

  • Guardant Health: Guardant Health is a precision oncology company specializing in liquid biopsy and blood-based cancer mutation profiling for therapy selection. Comparable in oncology CDx and gene mutation detection, though focused on liquid biopsy rather than tissue-based dPCR.
  • Personalis: Personalis is a precision oncology company offering tumor profiling and companion diagnostics services via NextGen sequencing. Comparable as a precision oncology player developing CDx products, though platform technology differs from Gencurix's dPCR focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Gencurix compliance and trust

Trust signal

Compliance2 records

Gencurix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gencurix leadership team

Management profile

Number of profiles

Gencurix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gencurix M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gencurix

What does Gencurix do?

Gencurix develops and sells digital PCR-based companion diagnostic (CDx) tests for precision oncology, detecting cancer-driving gene mutations to guide targeted therapy selection. Its product portfolio includes the Droplex PIK3CA Test for breast cancer and four CE-IVDR certified cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer). Products are sold as in vitro diagnostic kits/reagents to healthcare providers and laboratories globally through channel partners and direct market entries.

Is Gencurix a public or private company?

Gencurix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gencurix founded?

Gencurix was founded in 2011. It employs 11 to 50 people.

Where is Gencurix based?

Gencurix is headquartered in Seoul, South Korea, in the Asia region.

How does Gencurix make money?

Two revenue lines are on record. Digital PCR-based Companion Diagnostics are the primary driver. The others are CE-IVDR Certified Cancer Gene Tests.

Who are Gencurix's main competitors?

Direct peers on record are Asuragen (Bio-Techne), Amoy Diagnostics and Burning Rock Biotech. Broad incumbents are QIAGEN, Bio-Rad Laboratories, Roche Diagnostics, Exact Sciences and NeoGenomics. Emerging players are Guardant Health and Personalis.

Does Gencurix have an API?

No public API is recorded for Gencurix.

What industry is Gencurix in?

Gencurix's product category is Cancer Companion Diagnostics (Molecular Diagnostics / IVD). Its primary akta.pro industry code is HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingGencurix Faces Kosdaq Listing Eligibility Review, Potential DelistingKosdaq designated Gencurix for a substantive listing eligibility review, raising the possibility of delisting. A committee will decide on delisting or an improvement period within 20 business days of notification, by Nov. 30, 2026. An improvement plan submitted by Nov. 23, 2026, would trigger a 20-business-day decision window.PR NewswirePCR Technologies Market worth $21.43 billion by 2031 - Exclusive Report by MarketsandMarkets™The PCR technologies market is projected to grow from $15.55 billion in 2026 to $21.43 billion by 2031, a CAGR of 6.6%. North America held the largest share at 45% in 2025, and reagents and consumables accounted for 65% of the market. Digital PCR is expected to see the highest CAGR of 9.5%.KBRGencurix secures Thai approval for breast cancer PIK3CA companion diagnosticsGencurix announced that its Droplex PIK3CA Test received approval from Thailand's Food and Drug Administration in January, marking the company's second in vitro diagnostic authorization in Thailand for a digital PCR-based breast cancer companion diagnostic. The approval supports Gencurix's strategy to expand its precision breast cancer diagnostics in Southeast Asia and Eastern Europe, with demand increasing in Vietnam, Malaysia, and Slovenia. In 2025, Gencurix signed product development agreements with Bio-Rad Laboratories and QIAGEN and engaged in co-commercialization discussions with Roche Diagnostics, strengthening its foundation for global expansion.GlobeNewswiredPCR Market to Surpass US$14.34 Billion by 2031, Propelled by Escalating Demand for High‑Precision Genetic Analysis - New Industry Research by The Insight Partners.The global digital PCR (dPCR) market is projected to grow from US$7.52 billion in 2024 to US$14.34 billion by 2031, a CAGR of 9.4%. North America leads with a 10.3% CAGR, and clinical applications dominate while research shows the highest growth rate.openPR.comAnalysis of Key Market Segments Influencing the Breast Cancer Screening Test MarketThe breast cancer screening test market is forecast to reach $3.68 billion by 2030, growing at a compound annual growth rate of 8.1%, driven by personalized cancer screening protocols, AI-powered diagnostics, genetic testing, and increased investments in preventive oncology. In August 2024, Hitachi High-Tech Corporation formed a strategic partnership with South Korea-based Gencurix Inc. to develop molecular diagnostic services for cancer detection, leveraging Hitachi's expertise in in vitro diagnostics and digital technology. Additionally, Granules India Ltd. launched the Breast Health Express mobile screening unit in September 2024, equipped with mammography and ultrasound equipment to expand screening access in rural communities.MkGenCurix, a company specializing in cancer molecular diagnosis, announced on the 22nd that four canc..GenCurix, a cancer molecular diagnosis company, announced that four cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer) have obtained CE-IVDR certification meeting European In Vitro Diagnostic Regulation standards. This certification enables GenCurix to accelerate sales across Europe and convert all existing product lines from IVDD to the stricter IVDR system, while also strengthening an exclusive supply and sales contract with Bio-Rad Laboratories covering 32 European countries. The company also reported that foundations for joint development and global commercialization cooperation with global molecular diagnostic companies Roche and QIAGEN are taking shape.MkGenCurix, a precision medical molecular diagnostics company, announced on the 9th that it will parti..GenCurix, a precision medical molecular diagnostics company, announced it will participate in the 44th J.P. Morgan Healthcare Conference in San Francisco and hold meetings with the 'Big 3' global molecular diagnostic companies: Roche, QIAGEN, and Bio-Rad. The company aims to discuss business cooperation progress, expansion of digital PCR-based cancer diagnostic products including MRD and liquid biopsy tests, and strategies for entering the U.S. market including FDA approval and insurance registration. GenCurix stated it will accelerate entry into major global markets and diversify its profit structure through global partnerships.VocalMolecular Diagnostics Market Trends & SummaryThe global molecular diagnostics market reached USD 16.43 billion in 2024 and is projected to grow to USD 28.83 billion by 2033, driven by a 6.45% CAGR during 2025–2033, according to Renub Research. Growth is fueled by technological advances in PCR, sequencing, microarrays, and AI-enabled analytics, alongside rising disease prevalence and the shift toward personalized medicine. Key industry partnerships include Roche's September 2024 launch of the cobas Respiratory Flex Test and Hitachi High-Tech's August 2024 collaboration with Gencurix for cancer diagnostics.Cambridge NetworkBio-Rad extends partnership with Gencurix through strategic agreement for Droplet Digital™ PCR IVD Oncology Kits in EuropeBio-Rad has extended its partnership with Gencurix through a strategic agreement to distribute Droplet Digital™ PCR IVD Oncology Kits in Europe.